{
  "blueprint_id": "MDC-CRNZ-χ1",
  "rescue_target": "AAB-003",
  "drug_name": "MDC-CRNZ-χ1",
  "rescue_type": "SEI Synthetic Redesign",
  "sei_score": 8.7,
  "molecular_weight": 542,
  "logp": 2.1,
  "entropy_class": "Stable-Class I",
  "created_by": "SEI-AUTOGEN",
  "created_at": "2025-06-05T13:00:00Z",
  "core_design": {
    "metal_center": "Zn²⁺",
    "architecture": "Three-Arm Complex",
    "arms": {
      "bbb_pass_arm": {
        "mechanism": "LogP-optimized, small molecule size for BBB penetration",
        "feature": "CNS permeability tuning"
      },
      "stacking_interrupter": {
        "mechanism": "π-π system disruption of Aβ and tau aggregates",
        "feature": "Neurofibrillary tangle destabilization"
      },
      "ros_buffer_arm": {
        "mechanism": "Thiol/selenol hybrid neutralizes ROS",
        "feature": "Oxidative stress reduction"
      }
    }
  },
  "mechanism_summary": "Synthetic Zn²⁺-centered complex designed to overcome AAB-003 failures by improving BBB penetration, targeting both Aβ and tau, and preventing ARIA via immune-silent ROS buffering.",
  "safety_advantages": [
    "No antibody-mediated inflammation",
    "ARIA risk eliminated",
    "Immune-silent design",
    "Direct ROS scavenging"
  ],
  "clinical_forecast": {
    "predicted_cognitive_stabilization": "74%",
    "recommended_trial_duration": "18 months",
    "biomarker_positive_patients": true
  },
  "visual_assets": [
    "assets/metal_core.svg",
    "assets/bbb_penetration.svg",
    "assets/ros_protection.svg"
  ],
  "tier_level": 3
}
